Federico Gentile

Federico Gentile

Auto-generated profile, based on publicly available information

Federico Gentile

Pediatric Nephrology and Dialysis Unit, Pediatric Hospital “Giovanni XXIII”, Bari 70123, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2014 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
Fabio MidullaFabio Midulla
Fabio Midulla
ANAmbra Nicolai
Ambra Nicolai
MFMarianna Ferrara
Marianna Ferrara
FGFederico Gentile
Federico Gentile
APAlessandra Pierangeli
Alessandra Pierangeli
PPPaola Papoff
Paola Papoff

21 August 2013 in Early Human Development
Verified
Journal Article
Closed access
PDF file
ANAmbra Nicolai
Ambra Nicolai
MFM. Ferrara
M. Ferrara
CSC. Schiavariello
C. Schiavariello
FGF. Gentile
F. Gentile
MGM.E. Grande
M.E. Grande
Fabio MidullaFabio Midulla
Fabio Midulla

MGMario Giordano
Mario Giordano
Maria Elisabetta BaldassarreMaria Elisabetta Baldassarre
Maria Elisabetta Baldassarre
VPViviana Valeria Palmieri
Viviana Valeria Palmieri
DTDiletta Domenica Torres
Diletta Domenica Torres
VCVincenza Carbone
Vincenza Carbone
Nicola LaforgiaNicola Laforgia
Nicola Laforgia
Shiga toxin-producing Escherichia Coli (STEC) infections routinely run as a common gastroenteritis, but in many cases they may evolve towards hemolytic uremic syndrome (HUS). HUS is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Gut microorganisms have a fundamental impact on human physiology, because they modulate normal intestinal functions and play a pivotal role in influencing the local and systemic immune responses. Despite surveillance established in many countries and major progresses in the understanding of STEC-HUS mechanisms, no specific treatment is currently available. Targeting the gut microbiota could represent a new potential therapeutic strategy in STEC infection. In this paper, we reviewed the current knowledge about microbiota characteristics of patients with STEC infections, as well as in vitro and in vivo evidence of probiotic supplementation in managing STEC gastroenteritis and in HUS onset prevention.